Karolina Pokrzywka

Karolina Pokrzywka

Auto-generated profile, based on publicly available information

Karolina Pokrzywka

Faculty of Medicine, Tissue Engineering Department, Collegium Medicum, Nicolaus Copernicus University, Karłowicza 24, 85-092 Bydgoszcz, Poland.

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
AKAdriana Kaszuba
Adriana Kaszuba
JSJERZY SITKOWSKI
JERZY SITKOWSKI
Tadeusz Mikolaj MuziolTadeusz Mikolaj Muziol
Tadeusz Mikolaj Muziol
KPKarolina Pokrzywka
Karolina Pokrzywka
ŁKŁukasz Kaźmierski
Łukasz Kaźmierski
IŁIwona Łakomska
Iwona Łakomska
The main goal of our research was to examine (1S,4R,5R)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)-2-((S)-1-phenylethyl)-2-azabicyclo[3.2.1]octane (L) and its complex-forming abilities with platinum(ii) ions. We studied those complexes as potential anticancer prodrugs.

7 April 2022 in Life
Verified
Journal Article
Open access
PDF file
MMMalgorzata Maj
Malgorzata Maj
ŁKŁukasz Kaźmierski
Łukasz Kaźmierski
KBKarolina Balik
Karolina Balik
KKKarolina Kowalska
Karolina Kowalska
LGLidia Gackowska
Lidia Gackowska
TDTomasz Drewa
Tomasz Drewa
Stem cell-based therapies are considered one of the most promising disciplines in biomedicine. Bladder cancer patients could benefit from therapies directed to promote healing after invasive surgeries or to lessen urinary incontinence, a common side effect of both cancer itself and the treatment. However, the local delivery of cells producing large amounts of paracrine factors may alter interactions within the microenvironment. For this reason, reconstructive cellular therapies for patients with a history of cancer carry a potential risk of tumor reactivation. We used an indirect co-culture model to characterize the interplay between adipose-derived stem cells and bladder cancer cells. Incubation with ASCs increased MCP-1 secretion by bladder cancer cells (from 2.1-fold to 8.1-fold, depending on the cell line). Cancer cell-derived factors altered ASC morphology. Cells with atypical shapes and significantly enlarged volumes appeared within the monolayer. Incubation in a conditioned medium (CM) containing soluble mediators secreted by 5637 and HB-CLS-1 bladder cancer cell lines decreased ASC numbers by 47.5% and 45.7%. A significant increase in adhesion to ECM components, accompanied by reduced motility and sheet migration, was also observed after incubation in CM from 5637 and HB-CLS-1 cells. No differences were observed when ASCs were co-cultured with HT-1376 cells. Our previous and present results indicate that soluble mediators secreted by ASCs and bladder cancer cells induce opposite effects influencing cells that represent the non-muscle-invasive urinary bladder.

2 July 2026 in Dalton Transactions
Verified
Journal Article
Open access
AKAdriana Kaszuba
Adriana Kaszuba
JSJERZY SITKOWSKI
JERZY SITKOWSKI
TMTadeusz Muzioł
Tadeusz Muzioł
ATAgnieszka Tafelska-Kaczmarek
Agnieszka Tafelska-Kaczmarek
KPKarolina Pokrzywka
Karolina Pokrzywka
IŁIwona Łakomska
Iwona Łakomska
Four new azole-platinum(II) complexes with the general formulas cis-[PtCl2(L1)2] (1), cis-[PtCl2(L2)2] (2), trans-[PtCl2(L1)(DMSO)] (3), and trans-[PtCl2(L2)(DMSO)] (4), where L1 is 1-(benzofuran-2-yl)-2-(1H-1,2,4-triazol-1-yl)ethenone, L2 is (benzofuran-2-yl)-2-(1H-imidazol-1-yl)ethenone, and DMSO is dimethyl sulfoxide, were synthesized and fully characterized. The compositions of the coordination spheres were established using spectroscopic methods (1H, 13C, 15N, 195Pt NMR; IR; X-ray). Complexes (1) and (2) adopted cis geometries, featuring two triazole ligands L1 in (1) or two imidazole ligands L2 in (2), each coordinated through the nitrogen donor atom N4″, along with two chloride ions. In contrast, complexes (3) and (4) exhibited trans configurations and contained one azole ligand (L1 or L2), each coordinated via a nitrogen donor N4″ atom, an S-donor DMSO molecule, and two chloride ions. All complexes displayed moderate lipophilicity (logP = 0.92-1.12) and markedly reduced reactivity toward glutathione compared with cisplatin, reflecting the steric shielding provided by the azole ligands. Despite these favorable physicochemical features, only complex (1) demonstrated notable intrinsic in vitro cytotoxicity. It showed activity against a lung cancer cell line (A549) and four bladder cancer cell lines (T24, HT1376, 5637, and HB-CLS-1), with IC50 values ranging from 5.00 to 8.50 µM. Comparable toxicity was observed toward normal SV-HUC-1 urothelial cells (IC50 = 8.54 µM). Notably, complex (1) induced only minor alterations in the cell-cycle profile, suggesting a mechanism of action distinct from those of classical DNA-targeting platinum drugs. To improve its therapeutic performance, complex (1) was encapsulated in polymeric micelles formed by PEO-PPO-PEO triblock copolymers. This nanoformulation resulted in a striking increase in anticancer activity, yielding submicromolar IC50 values (0.13-0.94 µM). The corresponding toxicity toward normal SV-HUC-1 cells ranged from IC50 = 0.17 to 0.75 µM. The substantial increase in potency suggests that micellar delivery enhances intracellular accumulation while protecting the complex from premature deactivation. These results suggest that triazole-based platinum(II) complexes, particularly when combined with polymeric nanocarriers, may represent a promising system for further investigation in the development of platinum-based chemotherapeutic drugs.